Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1980 1
1984 1
1985 1
1989 1
1992 2
1994 3
1995 2
1996 2
1997 2
1998 2
2000 2
2001 1
2002 3
2003 3
2004 1
2005 1
2007 1
2009 1
2010 2
2011 2
2017 3
2018 1
2019 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

36 results

Results by year

Filters applied: . Clear all
Page 1
Showing results for vanasia
Your search for Vandasia retrieved no results
Galectin-3 and the Mineralocorticoid Receptor Antagonist Canrenone in Mild Heart Failure.
Clemenza F, Masson S, Conaldi PG, Di Carlo D, Boccanelli A, Mureddu GF, Gonzini L, Lucci D, Maggioni AP, Di Lenarda A, Nicolis EB, Vanasia M, Latini R; AREA IN-CHF Investigators. Clemenza F, et al. Circ J. 2017 Sep 25;81(10):1543-1546. doi: 10.1253/circj.CJ-17-0656. Epub 2017 Aug 31. Circ J. 2017. PMID: 28855452 Free article. Clinical Trial.
Canrenone on cardiovascular mortality in congestive heart failure: CanrenOne eFFects on cardiovascular mortality in patiEnts with congEstIve hearT failure: The COFFEE-IT study.
Derosa G, Maffioli P, Scelsi L, Bestetti A, Vanasia M, Cicero AFG, Spinardi L, Bentivenga C, Esposti DD, Caprio M, Borghi C, Pitt B, Cosentino E. Derosa G, et al. Pharmacol Res. 2019 Mar;141:46-52. doi: 10.1016/j.phrs.2018.11.037. Epub 2018 Nov 28. Pharmacol Res. 2019. PMID: 30502530
Ambulatory blood pressure parameters after canrenone addition to existing treatment regimens with maximum tolerated dose of angiotensin-converting enzyme inhibitors/angiotensin II type 1 receptor blockers plus hydrochlorothiazide in uncontrolled hypertensive patients.
Guasti L, Gaudio G, Lupi A, D'Avino M, Sala C, Mugellini A, Vulpis V, Felis S, Sarzani R, Vanasia M, Maffioli P, Derosa G. Guasti L, et al. Drug Des Devel Ther. 2017 Aug 4;11:2293-2300. doi: 10.2147/DDDT.S134826. eCollection 2017. Drug Des Devel Ther. 2017. PMID: 28831241 Free PMC article. Clinical Trial.
Efficacy and safety of two dosages of canrenone as add-on therapy in hypertensive patients taking ace-inhibitors or angiotensin II receptor blockers and hydrochlorothiazide at maximum dosage in a randomized clinical trial: The ESCAPE-IT trial.
Derosa G, Maffioli P, D'Avino M, Sala C, Mugellini A, Vulpis V, Felis S, Guasti L, Sarzani R, Bestetti A, Vanasia M, Gaudio G; ESCAPE-IT Trial Investigators group. Derosa G, et al. Cardiovasc Ther. 2017 Feb;35(1):47-54. doi: 10.1111/1755-5922.12235. Cardiovasc Ther. 2017. PMID: 27860389 Free PMC article. Clinical Trial.
36 results